Lansoprazol Alexin

Lansoprazole, the active ingredient in Lansoprazol Alexin, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is employed to manage conditions such as gastro‑esophageal reflux disease, erosive esophagitis and peptic ulcer disease in adult patients and improves patient quality of life.

GNH USA supplies Lansoprazol Alexin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal conditions.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by reducing gastric acidity. - Erosive esophagitis: promotes healing of inflamed esophageal tissue through acid suppression. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence by maintaining a higher gastric pH. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic environment.

Lansoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may improve with continued therapy. - Nausea: feeling of queasiness, sometimes accompanied by stomach discomfort. - Abdominal pain: cramping or discomfort in the upper abdomen.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing. - Clostridioides difficile infection: persistent diarrhea with possible colitis. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Liver enzyme elevation: signs of hepatic dysfunction, such as jaundice.

Before initiating therapy, consider the following precautions.

- Assess renal function: adjust use in patients with severe renal impairment. - Monitor for infection: prolonged acid suppression may increase risk of C. difficile. - Avoid long‑term use without supervision: reassess necessity after 8‑12 weeks. - Use caution in pregnancy: limited data, weigh benefits against potential risks. - Review concomitant medications: potential for drug‑drug interactions. - Store at ambient temperature: keep in the original container, protect from moisture.

Lansoprazole may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Ketoconazole: reduced absorption of the antifungal when taken together. - Atazanavir: decreased antiviral plasma concentrations, compromising efficacy. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent coagulation monitoring. - Digoxin: elevated serum levels may occur, necessitating dose adjustment. - Methotrexate: increased toxicity risk, especially at high doses.